These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26298833)

  • 1. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs.
    Pich EM; Collo G
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1437-47. PubMed ID: 26298833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P
    Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dopamine D3 receptor: From preclinical studies to the treatment of psychiatric disorders.
    Drago F
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1399-400. PubMed ID: 26278782
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.
    Waters S; Sonesson C; Svensson P; Tedroff J; Carta M; Ljung E; Gunnergren J; Edling M; Svanberg B; Fagerberg A; Kullingsjö J; Hjorth S; Waters N
    J Pharmacol Exp Ther; 2020 Jul; 374(1):113-125. PubMed ID: 32358046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
    Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
    Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
    Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
    McCormick PN; Wilson VS; Wilson AA; Remington GJ
    Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.
    Le Foll B; Payer D; Di Ciano P; Guranda M; Nakajima S; Tong J; Mansouri E; Wilson AA; Houle S; Meyer JH; Graff-Guerrero A; Boileau I
    Neuropsychopharmacology; 2016 Jan; 41(2):529-37. PubMed ID: 26089182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
    Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance.
    Maggio R; Aloisi G; Silvano E; Rossi M; Millan MJ
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S2-7. PubMed ID: 20123551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?
    Carli M; Kolachalam S; Aringhieri S; Rossi M; Giovannini L; Maggio R; Scarselli M
    Curr Neuropharmacol; 2018 Jan; 16(2):222-230. PubMed ID: 28521704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.
    Maggio R; Millan MJ
    Curr Opin Pharmacol; 2010 Feb; 10(1):100-7. PubMed ID: 19896900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2-like receptor agonists induce penile erection in male rats: differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus.
    Sanna F; Succu S; Hübner H; Gmeiner P; Argiolas A; Melis MR
    Behav Brain Res; 2011 Nov; 225(1):169-76. PubMed ID: 21784104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
    Malik P; Andersen MB; Peacock L
    Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2011 Sep; 666(1-3):43-52. PubMed ID: 21658377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.